A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Official Title

A Phase IB Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Summary:

The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible for cytotoxic therapy.

Trial Description

Primary Outcome:

  • Phase Ib: Number of Participants with Dose Limiting Toxicities (DLTs)
  • Phase Ib: Number of Participants with Adverse Events, Including Adverse Events of Special Interest and Serious Adverse Events
  • Phase Ib: Number of Participants with Clinically Significant Changes in Safety Measurements, Including Vital Signs, Physical Exam Findings, Electrocardiograms (ECGs) and Clinical Laboratory
  • Phase Ib: Mortality Rates, Including Thirty and Sixty Day
Secondary Outcome:
  • Overall Response Rate (ORR) (CR + CRi + CRp + Partial Remission/Partial Response [PR])
  • Duration of Response (DOR)
  • Time to Progression (TTP)
  • Progression-Free Survival (PFS)
  • Event-Free Survival (EFS)
  • Leukemia-Free Survival (LFS)
  • Overall Survival (OS)
  • Pharmacokinetics of Venetoclax Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t)
  • Pharmacokinetics of Venetoclax Maximum Observed Concentration (Cmax)
  • Pharmacokinetics of Cobimetinib Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t)
  • Pharmacokinetics of Cobimetinib Maximum Observed Concentration (Cmax)
  • Pharmacokinetics of Idasanutlin Maximum Observed Concentration (Cmax)
  • Pharmacokinetics of Idasanutlin Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t)
  • Number of Patients Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire
  • Complete remission (CR) + Complete Remission with Incomplete Blood Count Recovery (CRi) + Complete Remission with Incomplete Platelet Count Recovery (CRp)
  • CR + Complete Remission with Partial Hematologic Recovery (CRh) Rate
  • Rate of Transfusion Independence
  • Duration Of Transfusion Independence, Defined As The Number Of Consecutive Days Of Transfusion Independence, Measured From 1 Day After Last Transfusion To Disease Progression Or Subsequent Transfusion
  • Minimal Residual Disease (MRD) In The Bone Marrow To Evaluate The Depth Of Response

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society